



## **Pneumocystis pneumonia: pitfalls and hindrances to establish a reliable animal model**

Adélaïde Chesnay, Christophe Paget, Nathalie Heuzé-Vourc'h, Thomas Baranek, Guillaume Desoubes

### **► To cite this version:**

Adélaïde Chesnay, Christophe Paget, Nathalie Heuzé-Vourc'h, Thomas Baranek, Guillaume Desoubes. *Pneumocystis pneumonia: pitfalls and hindrances to establish a reliable animal model*. *Journal of Fungi*, 2022, 8 (2), pp.129. 10.3390/jof8020129 . hal-03687287

**HAL Id: hal-03687287**

**<https://univ-tours.hal.science/hal-03687287>**

Submitted on 3 Jun 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# ***Pneumocystis* pneumonia: pitfalls and hindrances to establish a reliable animal model**

**A. Chesnay<sup>1,2</sup>, C. Paget<sup>2</sup>, N. Heuzé-Vourc'h<sup>2</sup>, T. Baranek<sup>2</sup>, G. Desoubieux<sup>1,2</sup>**

*1 Service de Parasitologie-Mycologie-Médecine tropicale, Pôle biologie médicale, hôpital Bretonneau, CHRU de Tours (France)*

*2 Centre d'Etude des Pathologies Respiratoires (CEPR) Institut National de la Santé et de la Recherche Médicale U1100, Université de Tours (France)*

*Corresponding author:*

*Adélaïde Chesnay, Service de Parasitologie-Mycologie-Médecine tropicale, Pôle biologie médicale, hôpital Bretonneau, CHRU de Tours, bâtiment B2A, 1<sup>er</sup> étage, 2, boulevard Tonnellé, 37044 Tours cedex 9, France*

*E-mail : [adelaide.chesnay@univ-tours.fr](mailto:adelaide.chesnay@univ-tours.fr)*

*Word count for the Abstract: 174*

*Word count for the body of the text: 4916*

*Number of references: 120*

*Number of figures: 4*

*Number of tables: 3*

*Conflict of interest: none*

*Funding source: none*

## ABSTRACT

*Pneumocystis* pneumonia is a severe lung infection that occurs primarily in largely immunocompromised patients. Few treatment options exist and the mortality remains substantial. To develop new strategies in the fields of diagnosis and treatment, it appears critical to improve the scientific knowledge about the biology of the *Pneumocystis* agent and the course of the disease. In the absence of *in vitro* continuous culture system, *in vivo* animal studies represent a crucial cornerstone for addressing *Pneumocystis* pneumonia in laboratories. These models constitute an essential complement to clinical studies. Here, we provide an overview of the animal models of *Pneumocystis* pneumonia that were reported in the literature over the last 60 years. It summarizes the various technical parameters to consider in the preparation of the model and the interpretation of the limits / results of such studies. Overall, this review highlights the great heterogeneity of the variables studied: the choice of the host species and its genetics, the different immunosuppressive regimens to render animal susceptible, the experimental challenge, and the different validation methods of the model.

Keywords: *Pneumocystis* pneumonia, animal model, *Pneumocystis* spp., *in vivo*, infectious challenge.

## INTRODUCTION

*Pneumocystis* pneumonia is a lung infection involving *Pneumocystis jirovecii*, an ubiquitous fungus with opportunistic behavior (1). First described in malnourished children during and after World War II (2), fatal *Pneumocystis* pneumonia was one of the first signals of the AIDS epidemic in the United States in the early 1980s (3). The advent of antiretroviral drugs has resulted in a significant decrease in the incidence of *Pneumocystis* pneumonia in Human Immunodeficiency Virus (HIV)-positive patients. Today, in regions where HIV testing and treatment are available without restrictions, *Pneumocystis* pneumonia primarily occurs in subjects undergoing non-viral sources of immunosuppression. This includes pathological conditions responsible for the decrease of blood leucocytes such as hematological malignancies, auto-immune diseases, and drug-induced immunosuppression such as corticosteroids, TNF- $\alpha$  inhibitors, alkylating agents (4, 5). Actually, *Pneumocystis* pneumonia occurs mainly when risk factors are cumulative, *i.e.* immunosuppressive therapeutic associated to a fragile medical condition. Altogether, *Pneumocystis* pneumonia affects each year more than 500,000 patients worldwide. After *Candida* spp, *P. jirovecii* is the second most common fungal agent among invasive fungal infections (6). *Pneumocystis* pneumonia mortality is significant and has been estimated at 10-20% in HIV-positive patients and 20-40% in HIV-negative patients (7, 8).

Two main forms co-exist during *P. jirovecii* life cycle: the asexual and the trophic forms that are differentially involved. The transmission, which is human-to-human airborne, is ensured by the asexual form, the only form capable of living transiently in the external environment (9, 10). Next, the trophic forms thrive at the surface of type I-pneumocytes in the pulmonary alveoli. This leads to the generation of a local inflammation, while the infection remains extracellular and never becomes invasive in tissues (11, 12). Clinically non-specific, *Pneumocystis* pneumonia can manifest with fever associated with non-productive cough and chest pain (1, 13, 14). Chest scans usually show bilateral interstitial alveolar syndrome revealed by ground-

glass findings, that are non-pathognomonic of *Pneumocystis* pneumonia (15). The specific biological diagnosis relies on microbiological identification of *P. jirovecii* in pulmonary secretions / lung tissues by microscopic examination and qPCR. Likewise, it can be indirectly suggested by measuring (1,3)- $\beta$ -D-glucan, a polysaccharide component of the cell wall of *P. jirovecii* and other fungi, in the serum of patients (16, 17).

Despite some advance in the scientific knowledge, *Pneumocystis* pneumonia still contains many unknowns. The cycle of *Pneumocystis* is not fully elucidated yet, thus preventing from dispensing clear prevention guidelines. Concerning the pathophysiology, there is a critical need to investigate all the immune mechanisms integrated in the host response. Therefore, experimental models are essential to complete clinical studies. Although theoretically easier and sparing animal lives, *in vitro* models are unable to mimic the complexity of host-fungus interactions. Importantly, there is no *in vitro* continuous culture system for *Pneumocystis* spp., despite long research in this area (18, 19). Animal models can circumvent these limitations (20–22). Therefore, various animal models of *Pneumocystis* pneumonia have been developed in attempt to address pathogenesis, virulence, immune response, diagnosis or therapy concerns. However, a single model cannot answer all the aforementioned questions, which explains in part the great multiplicity of supports that have been developed so far. This variability can hind the scientific comparisons, and each mammal species has its own *Pneumocystis* species (e.g. *P. murina* for the mouse or *P. carini* for the rat). Of all the animal model variables, the investigator has to question at the pivotal experimental parameters and major technical features that are assumed to likely influence the results according to the question asked.

Here, we conducted an extensive literature review of published reports related to animal models of *Pneumocystis* pneumonia using a search strategy in the PubMed database for articles published up to December 2020, based on MeSH terms. Our electronic request about animal models of *Pneumocystis* pneumonia retrieved 1,444 publications. Experimental animal

97 studies were included when they met the following inclusion criteria: (a) the article was  
98 accessible and written in English; (b) the study was an original article, (c) the animal model  
99 was *not* exclusively used to produce *Pneumocystis* organisms for an *in vitro* study; (d) the  
100 study was *not* a *post hoc* analysis in laboratory or wild animals. After thorough reviewing, a  
101 total of 341 articles, corresponding to 749 distinct animal models, were finally retained for  
102 complete analysis (**Figure 1**). Initially, articles were mostly dedicated to the description of the  
103 implementation of animal models and to preclinical therapeutic studies (**Figure 2**). Then, at  
104 the beginning of the 2000s, pathophysiology studies became by far the largest area of  
105 experimentation. We now propose to the reader a progressive and in-depth review of the  
106 elements that we consider essentials in the design of an animal model of *Pneumocystis*  
107 pneumonia, *i.e.* the host species, the parameters inducing susceptibility to *Pneumocystis*  
108 pneumonia, , the implementation of the experimental infection (route of inoculation, fungal  
109 inoculum) and and the biological parameters to follow up to assert correct implementation of  
110 the disease the validation methods of the model.

## GENERAL DESCRIPTION OF THE VARIOUS ANIMAL MODELS: HOST SPECIES AND STRAINS, SEX, WEIGHT AND AGE

The choice of the host species is critical to reproduce as faithfully as possible the pathology that develops in Humans, but also to ensure the best reproducibility. Indeed, as in Humans, animals need to be carriers of *Pneumocystis* and transmit it to their congeners by air. Also, as in Humans, depending on their immune status, they must be able to eliminate the fungus naturally without developing a disease if they are immunocompetent, or on the contrary, in case of immunosuppression. Overall so far, more than ten animal species have been used as host models to *in vivo* study *Pneumocystis* pneumonia (**Table I**). Not surprisingly, rodents, were extensively exploited (95.9%) compared to other orders of mammals. Mice were used in 74.8% of the selected studies, compared to 20.8% and 0.3% for rats and other rodents (*e.g.* Guinea pigs and hamsters), respectively. The mouse model was widely used for its well characterized physiology, as well as biochemical and genetic homologies with Humans (23), but also for the dedicated toolbox that has been developed. Rabbits were used in 1.3% of the studies. Nonetheless, rabbits usually display lower fungal loads than other animals, and few tools and products are adapted to rabbit's biology. In addition, they are more expensive and difficult to handle than rats and mice. In 1.3% of the models, non-human primates (NHP) were used, from two species belonging to the family of Cercopithecidae (26–33). The latter, thanks to their physiological similarities and evolutionary conservation with Humans, represented privileged models for studying *Pneumocystis* pneumonia in a viral immunodeficiency background. Nevertheless, even if Humans and NHP are closely related, it should be kept in mind that, in normal conditions, each is contaminated by its own species, *P. jirovecii* for Humans and *P. macacae* for macaques. Other mammals were rarely used such as ferrets (34–36), pigs (37–39), cats (37) and dogs (37). Lastly, two arthropod-based studies, with *Drosophila melanogaster* and *Galleria mellonella*, assessed the non-susceptibility of

non-mammalian species to *Pneumocystis* pneumonia (40, 41). Depending on the purpose/issue of the study, some animals were used more frequently than others (**Figure 3**). Rabbits have most commonly been used to study the *Pneumocystis* agent and its transmission. Indeed, spontaneous *Pneumocystis* pneumonia is described in the absence of induced immunosuppression at the time of weaning, thus naturally facilitating its study (24, 25). Mice and rats have also been used to study the transmission of *Pneumocystis* between the same or different host species. Mice have been mostly used to study host-pathogen interactions and host immune response. Non-human primates have been little used, in part for ethical restrictions; but they have the great advantage to reproduce the development of *Pneumocystis* pneumonia in a context of virus-induced immunodepression. Finally, rats have been the preferred species for pre-clinical therapy studies (prophylactic, immunization, curative). The relative benefits and limitations of these models for the study of *Pneumocystis* pneumonia are summarized in the **Table II**.

The importance of an informed choice for the animals concerns not only the species, but also the strain. Focusing on mouse models, studies using inbred strains predominated: BALB/c and C57BL/6 were the more reported before C3H/HeN. Attention should be paid to the selection of strains, as highlighted in a study conducted by Swain *et al*, in which BALB/c and C57BL/6 mice have been shown to develop a specific early immune reaction after inoculation of *P. murina* (42). Strains also appeared to show a different permissiveness to *Pneumocystis* infection with variable lung burdens as shown by Tisdale *et al.* (43). Considering all animal models other than mice, outbred animals were used more frequently than inbred ones. For studies with outbred rats, Sprague-Dawley represented 64.1% of the rat models, while Wistar strain was associated with 14.7% reports. The data on susceptibility in different rat strains do not seem to be unanimous. Whereas Boylan *et al.* evaluated that Sprague-Dawley, Fisher 344, and Lewis rats immunosuppressed by steroid developed the same heavy infection six weeks after the inoculation, Hong *et al.* showed that Wistar rats developed an earlier and severer infection than Fisher and Sprague-Dawley rats under steroid immunosuppression (37, 44).



The sex of the animal chosen is also important although, in the majority of models (64.6%), it was not specified. When reported, they were females in 48.3%, males in 37.4%, and both genders in 14.3%. In a study comparing the progression of *Pneumocystis* pneumonia in male and female, Tisdale *et al.* showed that females of three distinct mouse strains had higher fungal burdens as compared to males after six weeks of infection (43). This contrasts with what is usually observed in Humans where men are the most affected by *Pneumocystis* pneumonia (45, 46). Concerning the weight of animals used, when informed (14.2%), it was quite homogeneous and standard with  $21.0 \pm 4.5\text{g}$  and  $189.4 \pm 48.4\text{g}$ , for mice and rats respectively. In models of *Pneumocystis* pneumonia, weight loss is rarely reported and appears as a poor and irrelevant indicator of disease. Moreover, in human medicine, there are very few data on the importance of the initial weight of patients suffering from *Pneumocystis* pneumonia, only a few cases reported in a context of nutritional deprivation (47, 48). In contrast, the choice of life stage of the animals may be an important element, especially considering that the immune system is not fully developed during the first weeks of life and strongly evolves throughout aging (49). Indeed, studies have compared the different life stages of mice in relation to the immune response: neonates showed a delay in the onset of the immune response due to an inadequate lung environment coupled with an inherent inability to develop a robust innate immune response to infection and an inexperienced adaptive immune system (50–52).

## SELECTION OF THE REGIMEN INDUCING SUSCEPTIBILITY TO *PNEUMOCYSTIS* PNEUMONIA

In the great majority of cases, tools to render animals susceptible to *Pneumocystis* pneumonia are an essential element to consider. Indeed, patients susceptible to *Pneumocystis* infection have the particularity of presenting pre-existing underlying conditions. Therefore, usage of a regimen inducing susceptibility to *Pneumocystis* pneumonia was reported in 663 animal models, *i.e.*, 88.5% of those described. The advantages and disadvantages of the principal strategies to render animal susceptible to *Pneumocystis* pneumonia are summarized in **Table III**.

Based on analogy with other models of fungal infections of the respiratory tract (*e.g.* aspergillosis), anti-cancerous drugs like alkylating substances, and more specifically cyclophosphamide, were used to induce adequate immunocompromised conditions (53, 54). However, alkylating agents primarily target neutrophils, that are less involved in the response to *Pneumocystis* than T-lymphocytes and macrophages. The latter are rather targeted by steroids, recognized as major risk factor for the development of *Pneumocystis* pneumonia (55–57). They have been largely used to induce immunosuppression in animal models of *Pneumocystis* pneumonia (30.8% of the animal models) (58–64). Dexamethasone administered in drinking water at a concentration of 1 to 4 mg/L was the most commonly used (57.8% of steroids models), ahead of injectable cortisone acetate (23.9% of steroids models) and injectable methylprednisolone (15.2% of steroids models), both administered subcutaneously. Dexamethasone has the advantage of a longer duration of action, but also a higher anti-inflammatory potency than cortisone and methylprednisolone. Oral administration is convenient, relatively safe, economical and compatible with refinement of experimental procedures, although it does not possess the highest bioavailability compared to parenteral routes of administration (65). In most models, steroid-dependent immunosuppression started

one to two weeks prior experimental challenge, in order to reproduce a suitable condition for the development of *Pneumocystis* pneumonia (66), and was continuously pursued until the infection had been established (67, 68). Other immunosuppressive drugs were alternatively used in rare models: dichloromethylene diphosphonate-containing liposomes or clodronate-liposomes for the specific depletion of macrophages (69, 70, 64), or more broad-spectrum medicines such as calcineurin inhibitors, tacrolimus and ciclosporin (71), mTOR inhibitor, sirolimus (72), or inhibitor of inosine-5'-monophosphate dehydrogenase, mycophenolate mofetil (72).

Considering that CD4<sup>+</sup> T-lymphocytes count is a reliable predictor of opportunistic *Pneumocystis* pneumonia during HIV infection (66), a more specific treatment of this lineage has also been tested. Depleting monoclonal antibodies (mAbs) targeting CD4<sup>+</sup> T-lymphocytes (clone GK1.5) were widely used (81.7% of these models based on immunotherapy) alone or in combination with other T-cell depleting mAbs such as anti-CD8 (clone 2.43) or anti-Thy1.2 (clone 30H12) mAbs in mice. Some other antibodies were given, such as anti-CD20 mAb (clone 5D2 or 18B12) allowing B cell depletion (73, 74). mAbs could be administered either once, before or just after the experimental infection, or several times throughout the course of infection. Immunotherapy was most often administered by intraperitoneal injection and almost exclusively in mice. Unfortunately, the risk of hypersensitivity reaction or cytokine release-associated acute reactions, and the multiplication of parenteral injections constitute major drawbacks (75, 76).

Genetically modified mice also offer interesting advantages for the development of *Pneumocystis* pneumonia and have been widely used (56.4% of the studies in mouse models). They can be grossly divided into two groups: 1) models displaying a general immunodeficiency such as SCID or RAG1<sup>-/-</sup> mice that lack functional T-cells and/or B-cells, or 2) more refined models that target a specific gene implicated in the host response. The first ones aforementioned were primarily used to study *Pneumocystis* biology including its life

cycle and efficiency of anti-*Pneumocystis* curative drugs. In 1993, the study by Chen *et al.* used CB17/scid (SCID) mice to support the concept that *Pneumocystis* pneumonia develops in immunocompromised patients because of recent exposure to an exogenous source and not necessarily because of reactivation of latent infection (77). The second ones were exploited to study and identify cellular and molecular entities involved in the innate and adaptive anti-*Pneumocystis* immune responses. For example, the involvement of the surfactant proteins A and D in fighting against *Pneumocystis* was highlighted by the generation of deficient mice that were knocked out for the relative encoding genes (78–84). Later in 2018, Elsegeiny *et al.* used several mouse models to recapitulate human primary immune disorders, enabling them to understand which types of CD4 T-cells were involved or relevant to mediate the clearance of *Pneumocystis* (22). However, care should be taken when interpreting outcomes in these models because of redundancy in the immune system and/or compensatory hyperactivity that can lead to confounding effects (85). In addition, scientists have to keep in mind that the use of such genetically modified or defined mice under standardized environmental conditions may influence host immunity and inflammation (86). While the generation of such mice still remains complicated, expensive and time consuming, they represent very useful biological tools for studying the host immune response to *Pneumocystis*.

Alternative immunosuppression procedures have also been implemented. This was the case for the majority of *Pneumocystis* pneumonia models in NHP. In order to reproduce as closely as possible the immunosuppression that affects AIDS patients, NHP were infected intravenously with Simian Immunodeficiency Virus (SIV) (26–32).

To enhance the magnitude of *Pneumocystis* infection, low protein diet was used in 7.9% of the models (87). This particular diet, harmful to longevity/metabolic health, was set up to reproduce the malnutrition status observed in some patients suffering from *Pneumocystis* pneumonia. However, it was quite expensive and barely used after the 2000s.

Since the models are mostly immunocompromised, it is important to use antibiotic prophylactic strategy to prevent from the occurrence of opportunistic bacterial infection, that would occur more quickly than the *Pneumocystis pneumonia*. Antibiotics were used in 23.0% of the models. The molecules used belonged to a broad spectrum of antibiotic families. Cyclins were the most widely used, in 70.9% of the models using antibiotics. Tetracycline was administered in drinking water at a concentration between 0.5 and 1 mg/mL, and doxycycline, by far less used, was administrated by subcutaneous injection. Beta-lactamins were used in 26.2% of the models, along with ampicillin, cephradine, penicillin G, amoxicillin with or without clavulanic acid. They were mostly administered in drinking water. Other antibiotics were less used, such as quinolones with ciprofloxacin (69), aminoglycosides with streptomycin and gentamicin (88, 89), or sulfamides with sulfadiazine (90). Anecdotally, 2.4% of the models used polyenes, nystatin or amphotericin B to prevent for other fungal diseases. The antibiotic prophylaxis strategy based on the use of cyclins, especially tetracycline, which is widely used, inexpensive and easily administered in drinking water, is to be preferred. Concerning the use of antibiotic prophylactic strategy, the parallel with what can be observed in human medicine is complicated to establish. Indeed, while most cases of *Pneumocystis pneumonia* occur in immunocompromised patients, little or no retrospective data are available on the use of antibiotics concomitant with the development and/or diagnosis of *Pneumocystis pneumonia*. Such information could be of interest in assessing the impact of such treatment might have on the pathophysiology of the disease.

## IMPLEMENTATION OF THE EXPERIMENTAL INFECTION

Setting up a relevant animal model of fungal infection first requires considering the route of infection. Three main methods of experimental challenge have been proposed in the literature for generating *Pneumocystis* pneumonia.

A first passive strategy was based on the presumed latency of *Pneumocystis* within the lung alveoli and its subsequent reactivation following the induction of immunosuppression. This strategy was adopted in 20.7% of the models, especially in the pioneer reports. With respect to the recent evidences rather in favor of a *de novo* infection, this protocol seemed clearly inadequate and moreover insufficient to ensure a methodologically strict and reproducible study. Indeed, in most of these ancient reports, animals were kept under unspecified exposure conditions, and the occurrence of *Pneumocystis* pneumonia was quite random and most likely due to the transmission of *Pneumocystis* organisms by the other animals housed in the same facilities. Nowadays, one acknowledges that it is essential to use animals with the SOPF (Specific and Opportunistic Pathogen Free) certification in housing conditions such as microisolator/filtered cages that eliminate the risk of transmission from other animals.

A second passive strategy, used in 17.0% of the studied models, was implemented by co-housing healthy animals with *Pneumocystis*-pre-infected seeder mate-fellows. Indeed, the airborne route was clearly established in the early 1980's in germ-free immunocompromised rats that had been exposed to potential sources of *Pneumocystis carinii* (*i.e.* natural *Pneumocystis* species in rats) (91). In isolators, animals exposed to filtered sterile air and unsterile water and food did not acquire *P. carinii*, while rats exposed in open cages to room air but maintained on sterile diet acquired the infection. Thus thanks to this model, it has been demonstrated that *Pneumocystis* was naturally acquired by horizontal transmission as an airborne organism in a *de novo* infection (67, 91, 92). In the same vein, healthy immunocompromised animals were co-housed with fellows of the same species infected with *Pneumocystis*, for a time varying from one day to several weeks (93–98). It appeared that

306 inoculum or dose effect determined the rate at infection progression (99). Although this kind  
307 of strategy replicates the natural transmission of *Pneumocystis* in mammals, it could lack  
308 control and reproducibility.

309 In order to control these points, a third experimental infection strategy was developed through  
310 the direct inoculation of *Pneumocystis* organisms into the animals' respiratory tract. Various  
311 modes of administration have been developed. Most of the time, animals were sedated or  
312 anesthetized prior delivery, in order to minimize struggling and sneezing. The anesthesia  
313 procedure and the operator skills were critical steps to achieve a robust and reliable infection  
314 (100). Inoculation of *Pneumocystis* organisms could be achieved by intranasal,  
315 oropharyngeal, intratracheal instillation or by transtracheal deposition. The intranasal  
316 instillation, consisting in the deposition of droplets of a *Pneumocystis* suspension close to the  
317 nostrils, appears as the softest methods (easiest and the least invasive technique). At the  
318 opposite, the transtracheal alternative requires to expose the trachea surgically to a direct  
319 injection of organisms inside. Intratracheal delivery of *Pneumocystis* via blunted - needle or  
320 feeding cannula allows refining of the procedure by getting rid of the surgical incision.

321 Overall, the direct inoculation strategy was the most common method used in mouse models,  
322 with a majority of administration based on intratracheal instillation (**Table I**). The frequency  
323 of *Pneumocystis* inoculation was generally based on a single administration, except for some  
324 specific studies that completed two or three successive inoculations, separated by two to  
325 twenty days (50, 101–104). Garvy *et al.* performed several inoculations to induce  
326 immunization (50), whereas Vuk *et al.* used a second inoculation to be certain that mice  
327 strains used, known to exhibit low levels of *Pneumocystis* infection according to them, were  
328 sufficiently exposed to *P. murina* organisms (104). None of the studies compared multiple  
329 inoculations vs. a single one; thus, it is difficult to appreciate whether this resulted in a greater  
330 infection. However, the time until the onset of *Pneumocystis* pneumonia was similar whatever

the number of inoculations used. The advantages and disadvantages of each strategy to implement *Pneumocystis* pneumonia are summarized in **Table III**.

Other concerns raised from the variability of the composition and the size of the *Pneumocystis* inoculum. Because, so far, *in vitro* production of *Pneumocystis* has not been successful, *Pneumocystis* were extracted, and mostly purified, from fresh or frozen pulmonary grindings of previously-infected animals. Extraction could be based on different methods, such as stomacher blending, ultrasonication or magnetic stirring (10, 105–107). Because *Pneumocystis* organisms can only be partially purified, inoculum will contained immune cells, cytokines, or other immune stimulators that may affect the host's pulmonary immune response. Thus, a control with lungs from healthy animals having undergone the same purification process seems essential.. In some rare publications, the animal received *Pneumocystis* asci from another animal species (40, 41, 108, 109). Although Walzer *et al.* initially showed that the sporadic transmission of *Pneumocystis* was possible between rats and mice (108), the opposite was subsequently demonstrated and definitively admitted (109). Furthermore, there was a great diversity in the way to count the number of *Pneumocystis* organisms in order to prepare the infectious suspension for the experimental challenge. When some counted only the asci through microscopic observation, others counted in addition the trophic forms (80, 110–112). Noteworthy, counting of trophic forms is a tedious task and requires a great deal of experience on the part of the microscopist, and taking trophic forms in account is also quite sensitive, since they were shown as insufficient to induce *Pneumocystis* pneumonia (9, 10, 111, 113). In a concern of homogeneity and scientific relevance, it seems more appropriate to consider and count only the asci for the inoculum. Large variations in the inoculum size, defined by the prior numbering of *Pneumocystis* forms, were observed, from  $1.0 \times 10^4$  to  $1.0 \times 10^8$  *Pneumocystis* forms, with an average around  $1.0 \times 10^6$  to  $1.0 \times 10^7$  *Pneumocystis* organisms. Thereafter, the experimentalist should be aware that the



356 establishment of the clinical *Pneumocystis* pneumonia is a long process requiring four to  
357 seven weeks after the inoculation

## VALIDATION OF THE MODEL AND OUTCOME PARAMETERS TO FOLLOW UP

In all the infectious animal models, it is essential to verify the effective infection or colonization and quantify the microorganism load. Since the clinical and radiological signatures of *Pneumocystis* are not specific, the use of histological / biological techniques was almost systematic, although none of these methods provided actual information about the viability of the fungal elements. Overall, 98.4% of the articles reported at least one histological or biological test (including microscopic approaches) to confirm that the experimental infection has been correctly implemented in the exposed animals or to assess the fungal burden. However, most of the models exploited only one technique (78.6%).

Microscopic observations of pulmonary secretions/lung sections/lung grindings slides, longtime considered as the reference standard to prove *Pneumocystis* pneumonia or colonization, have been largely described, in 81.8% of all models. These direct methods used different types of staining like Diff quick, Giemsa, Grocott methanamine silver nitrate (GMS), and toluidine blue O or calcofluor-blue brightener to demonstrate the presence of discoid *Pneumocystis* asci and/or ascospores and/or trophic forms. Microscopic approaches require substantial microscopic expertise, but they seem essential because they allow to distinguish quickly the asci forms, while being easy-to-implement and inexpensive methods.

Methods based on molecular biology like nucleic acid amplification by qPCR or fluorescence *in situ* hybridization (FISH) are more sensitive techniques. They are more refined to determine the fungal load (asci and trophic forms included), and could be used in various kinds of samples (lung tissues, bronchial-alveolar lavage fluids (BALF), or oral swab samples). They were widely used, in 31.8% of the models, with the following targets: mitochondrial large subunit (mtLSU) rRNA gene, 5.8 S rRNA gene or dihydrofolate reductase (DHFR) gene. As for other molecular biology methods, qPCR requires specialized

costly equipment and reagents, which are now available in a large number of laboratories. It should be noted that the primers used for *Pneumocystis jirovecii* usually do not overlap with those of other *Pneumocystis* spp., like *P. jirovecii*.

Other tools were used, such as detection of anti-*Pneumocystis* antibodies, performed in 6.9% of the models, or the blood / BALF detection of (1,3)- $\beta$ -D-glucan (17, 112, 114–116). The serology, never used alone, was attended by huge difficulties involving potential false-negative test results and is questionable with regard to the production of antibodies in immunocompromised animals. In Humans, its use is restricted to epidemiological questions (117). Detection of (1,3)- $\beta$ -D-glucan is not specific to *Pneumocystis* pneumonia and is quite costly.

In general, and whatever the type of study, to assess *Pneumocystis* presence, identify its forms, and ensure the most accurate quantification possible, the combination of a microscopic and a molecular biology technique appears the most suitable.

## CONCLUSION

*Pneumocystis* pneumonia is a severe respiratory disease that occurs especially in immunocompromised patients. Worldwide, the number of deaths due to *Pneumocystis* spp. is estimated at almost 250,000 (Gaffi data, 2017). In absence of models of continuous *in vitro* culture, *in vivo* animal studies represent a crucial cornerstone for the study of *Pneumocystis* pneumonia. However, it is important to keep in mind that *Pneumocystis* species are host-specific (35); they have progressively diverged several tens of millions years ago and co-evolved with their hosts, thus defining their host obligate nature (118, 119). Therefore, these models are imperfect, and we can wonder about the extrapolation of the results obtained with models using microorganisms genetically different from those infecting Humans.

Ethical considerations are important when planning the use of an animal model and should be governed by the “3 R’s” rule: Replacement, Reduction, and Refinement (120). Animal experiments should be designed in such a way that they allow statistically significant results with the smallest possible number of animals, while being robust and reproducible. In such a manner, the choice of the animal species and strains to study *Pneumocystis* pneumonia is decisive. As seen previously, the mouse seems to be the most suitable species. Refinement in animal models of *Pneumocystis* pneumonia can be achieved by choosing a mean of immunosuppression that avoids parenteral administration (same comment for the choice of antibiotics prophylaxis), and by using parameters other than the overall mortality to assess the disease progression.

Studying articles published for the last 60 years has enabled us to establish a wide range of criteria and factors to be considered for implementing an animal model to address *Pneumocystis* pneumonia. It requires to make choices to best answer the question posed and includes many elements such as permissiveness to infection, homology, analogy, and fidelity with Humans, reproducibility, ease of handling, safety, and of course cost. Thus, if one wonders about the cycle of *Pneumocystis*, it seems more relevant to replicate the natural

transmission of *Pneumocystis* in mammals by using co-housing of healthy animals with infected fellows, whether rodents with which we have the most experience, or NHP, whose *Pneumocystis* species is the closest phylogenetically to that of Humans. In contrast, in pre-clinical therapeutic studies that require rigorous design to obtain homogenous population, a model with an implementation of the infection by direct inoculation of *Pneumocystis* organisms allows necessary reproducibility and high control. For studies focusing on the understanding of the pathophysiology and particularly the host immune response, several types of models can be suggested. The first ones use refined genetically modified mice with a very specific immunodeficiency to study its specific involvement in the host response. The other ones study the immune response more generally, using models displaying general immunodeficiency such as genetically modified SCID or RAG1-/- mice, or animals immunosuppressed by the use of corticosteroids, the major iatrogenic risk factor of *Pneumocystis* pneumonia in Humans (55–57).

Finally according to our experience, we can propose a relevant example of an animal model to study the immune response that uses genetically modified or not and steroid immunosuppressed rodents (**Figure 4**), challenged by intranasal inoculation of *Pneumocystis murina* and validated by a microscopic and a molecular biology technique. However, the scientific debate is not close to be shut.

## REFERENCES

1. Salzer HJF, Schäfer G, Hoenigl M, Günther G, Hoffmann C, Kalsdorf B, Alanio A, Lange C. 2018. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with *Pneumocystis jirovecii* Pneumonia. *Respiration* 96:52–65.
2. Gajdusek DC. 1957. *Pneumocystis carinii*; etiologic agent of interstitial plasma cell pneumonia of premature and young infants. *Pediatrics* 19:543–565.
3. Centers for Disease Control (CDC). 1982. A cluster of Kaposi's sarcoma and *Pneumocystis carinii* pneumonia among homosexual male residents of Los Angeles and Orange Counties, California. *MMWR Morb Mortal Wkly Rep* 31:305–307.
4. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, Fresnel A, Guiguen C, Le Tulzo Y, Jégo P, Tattevin P. 2014. Incidence of *Pneumocystis jirovecii* pneumonia among groups at risk in HIV-negative patients. *Am J Med* 127:1242.e11–17.
5. Thomas CF, Limper AH. 2004. *Pneumocystis pneumonia*. *N Engl J Med* 350:2487–2498.
6. Bongomin F, Gago S, Oladele RO, Denning DW. 2017. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. *J Fungi (Basel)* 3:57.
7. Asai N, Motojima S, Ohkuni Y, Matsunuma R, Nakashima K, Iwasaki T, Nakashita T, Otsuka Y, Kaneko N. 2012. Early diagnosis and treatment are crucial for the survival of *Pneumocystis pneumonia* patients without human immunodeficiency virus infection. *J Infect Chemother* 18:898–905.
8. Li M-C, Lee N-Y, Lee C-C, Lee H-C, Chang C-M, Ko W-C. 2014. *Pneumocystis jirovecii* pneumonia in immunocompromised patients: Delayed diagnosis and poor outcomes in non-HIV-infected individuals. *Journal of Microbiology, Immunology and Infection* 47:42–47.

9. Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. 2010. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 5:e8524.
10. Martinez A, Halliez MCM, Aliouat EM, Chabé M, Standaert-Vitse A, Fréal E, Gantois N, Pottier M, Pinon A, Dei-Cas E, Aliouat-Denis C-M. 2013. Growth and airborne transmission of cell-sorted life cycle stages of *Pneumocystis carinii*. PLoS ONE 8:e79958.
11. Limper AH, Martin WJ. 1990. *Pneumocystis carinii*: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest 85:391–396.
12. Ng VL, Yajko DM, Hadley WK. 1997. Extrapulmonary pneumocystosis. Clin Microbiol Rev 10:401–418.
13. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL. 1984. *Pneumocystis carinii* pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100:663–671.
14. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, Maubon D, Debourgogne A, Le Gal S, Dalle F, Leterrier M, Toubas D, Pomares C, Bellanger AP, Bonhomme J, Berry A, Durand-Joly I, Magne D, Pons D, Hennequin C, Maury E, Roux P, Azoulay É. 2014. *Pneumocystis jirovecii* pneumonia in patients with or without AIDS, France. Emerging Infect Dis 20:1490–1497.
15. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, Ohmagari N, Ohta H, Araoka H, Kikuchi Y, Yasui M, Inuzuka K, Goto H. 2010. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 49:273–281.
16. Desoubeaux G, Franck-Martel C, Caille A, Drillaud N, Lestrade Carluer de Kyvon M-A, Bailly É, Chandenier J. 2017. Use of calcofluor-blue brightener for the diagnosis of *Pneumocystis*

492 jirovecii pneumonia in bronchial-alveolar lavage fluids: A single-center prospective study. *Med*  
493 *Mycol* 55:295–301.

494 17. Desoubeaux G, Chesnay A, Mercier V, Bras-Cachinho J, Moshiri P, Eymieux S, De Kyvon M-  
495 A, Lemaigen A, Goudeau A, Bailly É. 2019. Combination of  $\beta$ -(1, 3)-D-glucan testing in  
496 serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of *Pneumocystis jirovecii*  
497 pneumonia. *Mycoses* 62:1015–1022.

498 18. Atzori C, Aliouat EM, Bartlett MS, Dujardin L, Cargnel A, Dei-Cas E. 1998. Current in vitro  
499 culture systems for *Pneumocystis*. *FEMS Immunol Med Microbiol* 22:169–172.

500 19. Schildgen V, Mai S, Khalfaoui S, Lüsebrink J, Pieper M, Tillmann RL, Brockmann M,  
501 Schildgen O. 2014. *Pneumocystis jirovecii* can be productively cultured in differentiated CuFi-  
502 8 airway cells. *mBio* 5:e01186-01114.

503 20. Walzer PD, Young LS. 1984. Clinical relevance of animal models of *Pneumocystis carinii*  
504 pneumonia. *Diagn Microbiol Infect Dis* 2:1–6.

505 21. Ceré N, Polack B. 1999. Animal pneumocystosis: a model for man. *Vet Res* 30:1–26.

506 22. Elsegeiny W, Zheng M, Eddens T, Gallo RL, Dai G, Trevejo-Nunez G, Castillo P, Kracinovsky  
507 K, Cleveland H, Horne W, Franks J, Pociask D, Pilarski M, Alcorn JF, Chen K, Kolls JK.  
508 2018. Murine models of *Pneumocystis* infection recapitulate human primary immune disorders.  
509 *JCI Insight* 3:e91894.

510 23. Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K, Birney E, Rogers J,  
511 Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE,  
512 Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P,  
513 Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell  
514 RD, Carninci P, Cawley S, Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C,  
515 Collins FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly  
516 M, David R, Davies J, Delehaunty KD, Deri J, Dermitzakis ET, Dewey C, Dickens NJ,



517 Diekhans M, Dodge S, Dubchak I, Dunn DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyra  
 518 E, Felsenfeld A, Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey TS,  
 519 Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt L, Grafham D, Graves TA,  
 520 Green ED, Gregory S, Guigó R, Guyer M, Hardison RC, Haussler D, Hayashizaki Y, Hillier  
 521 LW, Hinrichs A, Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I, Jaffe DB,  
 522 Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK, Karolchik D, Kasprzyk A,  
 523 Kawai J, Keibler E, Kells C, Kent WJ, Kirby A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas  
 524 EJ, Kulp D, Landers T, Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S,  
 525 Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH, McCarthy M, McCombie  
 526 WR, McLaren S, McLay K, McPherson JD, Meldrim J, Meredith B, Mesirov JP, Miller W,  
 527 Miner TL, Mongin E, Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash  
 528 WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O'Connor MJ, Okazaki Y, Oliver K,  
 529 Overton-Larty E, Pachter L, Parra G, Pepin KH, Peterson J, Pevzner P, Plumb R, Pohl CS,  
 530 Poliakov A, Ponce TC, Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM,  
 531 Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J, Schwartz MS, Schwartz S,  
 532 Scott C, Seaman S, Searle S, Sharpe T, Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G,  
 533 Smit A, Smith DR, Spencer B, Stabenau A, Stange-Thomann N, Sugnet C, Suyama M, Tesler  
 534 G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C, Ureta-Vidal A, Vinson JP, Von  
 535 Niederhausern AC, Wade CM, Wall M, Weber RJ, Weiss RB, Wendl MC, West AP,  
 536 Wetterstrand K, Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson RK,  
 537 Winter E, Worley KC, Wyman D, Yang S, Yang S-P, Zdobnov EM, Zody MC, Lander ES.  
 538 2002. Initial sequencing and comparative analysis of the mouse genome. *Nature* 420:520–562.

539 24. Cere N, Drouet-Viard F, Dei-Cas E, Chanteloup N, Coudert P. 1997. In utero transmission of  
 540 *Pneumocystis carinii* sp. f. *oryctolagi*. *Parasite* 4:325–330.

541 25. Sanchez CA, Chabé M, Aliouat EM, Durand-Joly I, Gantois N, Conseil V, López C, Duriez T,  
 542 Dei-Cas E, Vargas SL. 2007. Exploring transplacental transmission of *Pneumocystis oryctolagi*  
 543 in first-time pregnant and multiparous rabbit does. *Med Mycol* 45:701–707.

- 544 26. Furuta T, Fujita M, Mukai R, Sakakibara I, Sata T, Miki K, Hayami M, Kojima S, Yoshikawa  
545 Y. 1993. Severe pulmonary pneumocystosis in simian acquired immunodeficiency syndrome  
546 induced by simian immunodeficiency virus: its characterization by the polymerase-chain-  
547 reaction method and failure of experimental transmission to immunodeficient animals. *Parasitol*  
548 *Res* 79:624–628.
- 549 27. Patil SP, Board KF, Lebedeva IP, Norris KA. 2003. Immune responses to *Pneumocystis*  
550 colonization and infection in a simian model of AIDS. *J Eukaryot Microbiol* 50 Suppl:661–  
551 662.
- 552 28. Board KF, Patil S, Lebedeva I, Capuano S, Trichel AM, Murphey-Corb M, Rajakumar PA,  
553 Flynn JL, Haidaris CG, Norris KA. 2003. Experimental *Pneumocystis carinii* pneumonia in  
554 simian immunodeficiency virus-infected rhesus macaques. *J Infect Dis* 187:576–588.
- 555 29. Kling HM, Shipley TW, Patil S, Morris A, Norris KA. 2009. *Pneumocystis* colonization in  
556 immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques. *J*  
557 *Infect Dis* 199:89–96.
- 558 30. Kling HM, Shipley TW, Patil SP, Kristoff J, Bryan M, Montelaro RC, Morris A, Norris KA.  
559 2010. Relationship of *Pneumocystis jiroveci* humoral immunity to prevention of colonization  
560 and chronic obstructive pulmonary disease in a primate model of HIV infection. *Infect Immun*  
561 78:4320–4330.
- 562 31. Kling HM, Shipley TW, Guyach S, Tarantelli R, Morris A, Norris KA. 2014. Trimethoprim-  
563 sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-  
564 colonized nonhuman primates with SHIV infection. *J Acquir Immune Defic Syndr* 65:381–389.
- 565 32. Kling HM, Norris KA. 2016. Vaccine-Induced Immunogenicity and Protection Against  
566 *Pneumocystis* Pneumonia in a Nonhuman Primate Model of HIV and *Pneumocystis*  
567 Coinfection. *J Infect Dis* 213:1586–1595.

- 568 33. Cobos Jiménez V, Rabacal W, Rayens E, Norris KA. 2019. Immunization with *Pneumocystis*  
569 recombinant KEX1 induces robust and durable humoral responses in immunocompromised  
570 non-human primates. *Hum Vaccin Immunother* 15:2075–2080.
- 571 34. Stokes DC, Gigliotti F, Rehg JE, Snellgrove RL, Hughes WT. 1987. Experimental  
572 *Pneumocystis carinii* pneumonia in the ferret. *Br J Exp Pathol* 68:267–276.
- 573 35. Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. 1993. *Pneumocystis carinii* is not  
574 universally transmissible between mammalian species. *Infect Immun* 61:2886–2890.
- 575 36. Simpson-Haidaris PJ, Courtney MA, Wright TW, Goss R, Harmsen A, Gigliotti F. 1998.  
576 Induction of fibrinogen expression in the lung epithelium during *Pneumocystis carinii*  
577 pneumonia. *Infect Immun* 66:4431–4439.
- 578 37. Hong S, Park K, Lee S. 1992. Susceptibility of various animals to *Pneumocystis carinii*  
579 infection. *Kisaengch'ung hak chapchi The Korean journal of parasitology* 30:277–81.
- 580 38. Nielsen J, Bille-Hansen V, Settnes OP. 1999. Experimental corticosteroid induction of  
581 *Pneumocystis carinii* pneumonia in piglets. *APMIS* 107:921–928.
- 582 39. Nielsen J, Settnes OP, Henriksen SA, Jorsal SE, Bille-Hansen V. 1997. *Pneumocystis carinii*  
583 pneumonia--pig provocation model. *J Eukaryot Microbiol* 44:31S.
- 584 40. Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. 2010.  
585 Toll-deficient *Drosophila* are resistant to infection by *Pneumocystis* spp.: additional evidence  
586 of specificity to mammalian hosts. *Virulence* 1:523–525.
- 587 41. Fuchs BB, Bishop LR, Kovacs JA, Mylonakis E. 2011. *Galleria mellonella* are resistant to  
588 *Pneumocystis murina* infection. *Mycopathologia* 171:273–277.
- 589 42. Swain SD, Meissner NN, Siemsen DW, McInnerney K, Harmsen AG. 2012. *Pneumocystis*  
590 elicits a STAT6-dependent, strain-specific innate immune response and airway  
591 hyperresponsiveness. *Am J Respir Cell Mol Biol* 46:290–298.

- 592 43. Tisdale NL, Ashbaugh A, Hendrix K, Collins MS, Porollo AP, Cushion MT. 2019. The Effects  
593 of Sex and Strain on *Pneumocystis murina* Fungal Burdens in Mice. *bioRxiv* 781245.
- 594 44. Boylan C, Current W. 1992. Improved rat model of *Pneumocystis carinii* pneumonia: induced  
595 laboratory infections in *Pneumocystis*-free animals. *Infection and immunity* 60.
- 596 45. Bitar D, Lortholary O, Dromer F, Coignard B, Che D. 2013. Mycoses invasives en France  
597 métropolitaine, PMSI 2001–2010: incidence, létalité et tendances. *Bulletin Épidémiologique*  
598 *Hebdomadaire* 12–13:109–114.
- 599 46. Wickramasekaran RN, Jewell MP, Sorvillo F, Kuo T. 2017. The changing trends and profile of  
600 pneumocystosis mortality in the United States, 1999-2014. *Mycoses* 60:607–615.
- 601 47. Halabieh NAE, Petrillo E, Laviano A, Delfino M, Fanelli FR. 2016. A Case of *Pneumocystis*  
602 *jirovecii* Pneumonia in a Severely Malnourished, HIV-Negative Patient. *Journal of Parenteral*  
603 *and Enteral Nutrition* 40:722–724.
- 604 48. Hanachi M, Bohem V, Bemer P, Kayser N, de Truchis P, Melchior J-C. 2018. Negative role of  
605 malnutrition in cell-mediated immune response: *Pneumocystis jirovecii* pneumonia (PCP) in a  
606 severely malnourished, HIV-negative patient with anorexia nervosa. *Clin Nutr ESPEN* 25:163–  
607 165.
- 608 49. Partridge L, Deelen J, Slagboom PE. 2018. Facing up to the global challenges of ageing. *Nature*  
609 561:45–56.
- 610 50. Garvy BA, Harmsen AG. 1996. Susceptibility to *Pneumocystis carinii* infection: host responses  
611 of neonatal mice from immune or naive mothers and of immune or naive adults. *Infect Immun*  
612 64:3987–3992.
- 613 51. Garvy BA, Qureshi MH. 2000. Delayed inflammatory response to *Pneumocystis carinii*  
614 infection in neonatal mice is due to an inadequate lung environment. *J Immunol* 165:6480–  
615 6486.

- 616 52. Kurkjian C, Hollifield M, Lines JL, Rogosky A, Empey KM, Qureshi M, Brown SA, Garvy  
617 BA. 2012. Alveolar Macrophages in Neonatal Mice Are Inherently Unresponsive to  
618 *Pneumocystis murina* Infection. *Infection and Immunity* 80:2835–2846.
- 619 53. Weisbroth SH, Geistfeld J, Weisbroth SP, Williams B, Feldman SH, Linke MJ, Orr S, Cushion  
620 MT. 1999. Latent *Pneumocystis carinii* infection in commercial rat colonies: comparison of  
621 inductive immunosuppressants plus histopathology, PCR, and serology as detection methods. *J*  
622 *Clin Microbiol* 37:1441–1446.
- 623 54. Desoubeaux G, Cray C. 2017. Rodent Models of Invasive Aspergillosis due to *Aspergillus*  
624 *fumigatus*: Still a Long Path toward Standardization. *Front Microbiol* 8:841.
- 625 55. Yale SH, Limper AH. 1996. *Pneumocystis carinii* pneumonia in patients without acquired  
626 immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin*  
627 *Proc* 71:5–13.
- 628 56. Bienvenu A-L, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. 2016. *Pneumocystis*  
629 pneumonia suspected cases in 604 non-HIV and HIV patients. *Int J Infect Dis* 46:11–17.
- 630 57. Liu C-J, Lee T-F, Ruan S-Y, Yu C-J, Chien J-Y, Hsueh P-R. 2019. Clinical characteristics,  
631 treatment outcomes, and prognostic factors of *Pneumocystis pneumonia* in non-HIV-infected  
632 patients. *Infect Drug Resist* 12:1457–1467.
- 633 58. Shellito JE, Tate C, Ruan S, Kolls J. 2000. Murine CD4<sup>+</sup> T lymphocyte subsets and host  
634 defense against *Pneumocystis carinii*. *J Infect Dis* 181:2011–2017.
- 635 59. Swain SD, Wright TW, Degel PM, Gigliotti F, Harmsen AG. 2004. Neither neutrophils nor  
636 reactive oxygen species contribute to tissue damage during *Pneumocystis pneumonia* in mice.  
637 *Infect Immun* 72:5722–5732.

- 638 60. Lim H-Y, Müller N, Herold MJ, van den Brandt J, Reichardt HM. 2007. Glucocorticoids exert  
639 opposing effects on macrophage function dependent on their concentration. *Immunology*  
640 122:47–53.
- 641 61. Eddens T, Elsegeiny W, Nelson MP, Horne W, Campfield BT, Steele C, Kolls JK. 2015.  
642 Eosinophils Contribute to Early Clearance of *Pneumocystis murina* Infection. *J Immunol*  
643 195:185–193.
- 644 62. Nandakumar V, Hebrink D, Jenson P, Kottom T, Limper AH. 2017. Differential Macrophage  
645 Polarization from *Pneumocystis* in Immunocompetent and Immunosuppressed Hosts: Potential  
646 Adjunctive Therapy during Pneumonia. *Infect Immun* 85.
- 647 63. Cain DW, Cidlowski JA. 2017. Immune regulation by glucocorticoids. *Nat Rev Immunol*  
648 17:233–247.
- 649 64. Bhagwat SP, Gigliotti F, Wang J, Wang Z, Notter RH, Murphy PS, Rivera-Escalera F, Malone  
650 J, Jordan MB, Elliott MR, Wright TW. 2018. Intrinsic Programming of Alveolar Macrophages  
651 for Protective Antifungal Innate Immunity Against *Pneumocystis* Infection. *Front Immunol*  
652 9:2131.
- 653 65. Turner PV, Brabb T, Pekow C, Vasbinder MA. 2011. Administration of substances to  
654 laboratory animals: routes of administration and factors to consider. *J Am Assoc Lab Anim Sci*  
655 50:600–613.
- 656 66. Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, Suffredini AF,  
657 Deyton L, Kovacs JA, Falloon J. 1989. CD4 counts as predictors of opportunistic pneumonias  
658 in human immunodeficiency virus (HIV) infection. *Ann Intern Med* 111:223–231.
- 659 67. Wolff L, Horch S, Gemsa D. 1993. The development of *Pneumocystis carinii* pneumonia in  
660 germ-free rats requires immunosuppression and exposure to the *Pneumocystis carinii* organism.  
661 *Comp Immunol Microbiol Infect Dis* 16:73–76.

- 662 68. O’Leary TJ, Tsai MM, Wright CF, Cushion MT. 1995. Use of semiquantitative PCR to assess  
663 onset and treatment of *Pneumocystis carinii* infection in rat model. *J Clin Microbiol* 33:718–  
664 724.
- 665 69. Limper AH, Hoyte JS, Standing JE. 1997. The role of alveolar macrophages in *Pneumocystis*  
666 *carinii* degradation and clearance from the lung. *J Clin Invest* 99:2110–2117.
- 667 70. Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, Lee C-H. 2006. Suppression of  
668 alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis  
669 pneumonia. *J Immunol* 176:6443–6453.
- 670 71. Hughes WT, Smith B. 1982. Provocation of infection due to *Pneumocystis carinii* by  
671 cyclosporin A. *J Infect Dis* 145:767.
- 672 72. Oz HS, Hughes WT. 1997. Novel anti-*Pneumocystis carinii* effects of the immunosuppressant  
673 mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and  
674 dexamethasone. *J Infect Dis* 175:901–904.
- 675 73. Elsegeiny W, Eddens T, Chen K, Kolls JK. 2015. Anti-CD20 Antibody Therapy and  
676 Susceptibility to *Pneumocystis Pneumonia*. *Infect Immun* 83:2043–2052.
- 677 74. Opata MM, Hollifield ML, Lund FE, Randall TD, Dunn R, Garvy BA, Feola DJ. 2015. B  
678 Lymphocytes Are Required during the Early Priming of CD4<sup>+</sup> T Cells for Clearance of  
679 *Pneumocystis* Infection in Mice. *J Immunol* 195:611–620.
- 680 75. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. 2010. The safety and side  
681 effects of monoclonal antibodies. *Nat Rev Drug Discov* 9:325–338.
- 682 76. Akarsu A, Soyer O, Sekerel BE. 2020. Hypersensitivity Reactions to Biologicals: from Bench  
683 to Bedside. *Curr Treat Options Allergy* 7:71–83.
- 684 77. Chen W, Gigliotti F, Harmsen AG. 1993. Latency is not an inevitable outcome of infection  
685 with *Pneumocystis carinii*. *Infect Immun* 61:5406–5409.

78. Linke MJ, Harris CE, Korfhagen TR, McCormack FX, Ashbaugh AD, Steele P, Whitsett JA, Walzer PD. 2001. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to *Pneumocystis carinii* infection. *J Infect Dis* 183:943–952.
79. Atochina EN, Beck JM, Preston AM, Haczku A, Tomer Y, Scanlon ST, Fusaro T, Casey J, Hawgood S, Gow AJ, Beers MF. 2004. Enhanced lung injury and delayed clearance of *Pneumocystis carinii* in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen-nitrogen species. *Infect Immun* 72:6002–6011.
80. Atochina EN, Gow AJ, Beck JM, Haczku A, Inch A, Kadire H, Tomer Y, Davis C, Preston AM, Poulain F, Hawgood S, Beers MF. 2004. Delayed clearance of *pneumocystis carinii* infection, increased inflammation, and altered nitric oxide metabolism in lungs of surfactant protein-D knockout mice. *J Infect Dis* 189:1528–1539.
81. Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P. 2005. Surfactant protein A limits *Pneumocystis murina* infection in immunosuppressed C3H/HeN mice and modulates host response during infection. *Microbes Infect* 7:748–759.
82. Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P. 2006. Efficient resolution of *Pneumocystis murina* infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression. *J Med Microbiol* 55:143–147.
83. Linke MJ, Ashbaugh AA, Koch JV, Levin L, Tanaka R, Walzer PD. 2009. Effects of surfactant protein-A on the interaction of *Pneumocystis murina* with its host at different stages of the infection in mice. *J Eukaryot Microbiol* 56:58–65.
84. Linke MJ, Ashbaugh AD, Demland JA, Walzer PD. 2009. *Pneumocystis murina* colonization in immunocompetent surfactant protein A deficient mice following environmental exposure. *Respir Res* 10:10.



- 709 85. Rudmann DG, Preston AM, Moore MW, Beck JM. 1998. Susceptibility to *Pneumocystis*  
710 *carinii* in mice is dependent on simultaneous deletion of IFN-gamma and type 1 and 2 TNF  
711 receptor genes. *J Immunol* 161:360–366.
- 712 86. Enriquez J, Mims BMD, Trasti S, Furr KL, Grisham MB. 2020. Genomic, microbial and  
713 environmental standardization in animal experimentation limiting immunological discovery.  
714 *BMC Immunology* 21:50.
- 715 87. Walzer PD, LaBine M, Redington TJ, Cushion MT. 1984. Predisposing factors in  
716 *Pneumocystis carinii* pneumonia: effects of tetracycline, protein malnutrition, and  
717 corticosteroids on hosts. *Infect Immun* 46:747–753.
- 718 88. Sheldon WH. 1959. Experimental pulmonary *Pneumocystis carinii* infection in rabbits. *J Exp*  
719 *Med* 110:147–160.
- 720 89. Walzer PD, Runck J, Orr S, Foy J, Steele P, White M. 1997. Clinically used antimicrobial  
721 drugs against experimental pneumocystosis, singly and in combination: analysis of drug  
722 interactions and efficacies. *Antimicrob Agents Chemother* 41:242–250.
- 723 90. Hussain Z, Carlson ML, Craig ID, Lannigan R. 1985. Efficacy of tetroxoprim/sulphadiazine in  
724 the treatment of *Pneumocystis carinii* pneumonitis in rats. *J Antimicrob Chemother* 15:575–  
725 578.
- 726 91. Hughes WT. 1982. Natural mode of acquisition for de novo infection with *Pneumocystis*  
727 *carinii*. *J Infect Dis* 145:842–848.
- 728 92. An CL, Gigliotti F, Harmsen AG. 2003. Exposure of immunocompetent adult mice to  
729 *Pneumocystis carinii* f. sp. *muris* by cohousing: growth of *P. carinii* f. sp. *muris* and host  
730 immune response. *Infect Immun* 71:2065–2070.

- 731 93. Roths JB, Sidman CL. 1992. Both immunity and hyperresponsiveness to *Pneumocystis carinii*  
732 result from transfer of CD4<sup>+</sup> but not CD8<sup>+</sup> T cells into severe combined immunodeficiency  
733 mice. *J Clin Invest* 90:673–678.
- 734 94. Yasuoka A, Oka S, Komuro K, Shimizu H, Kitada K, Nakamura Y, Shibahara S, Takeuchi T,  
735 Kondo S, Shimada K. 1995. Successful treatment of *Pneumocystis carinii* Pneumonia in mice  
736 with benanomicin A (ME1451). *Antimicrob Agents Chemother* 39:720–724.
- 737 95. Gigliotti F, Garvy BA, Harmsen AG. 1996. Antibody-mediated shift in the profile of  
738 glycoprotein A phenotypes observed in a mouse model of *Pneumocystis carinii* pneumonia.  
739 *Infect Immun* 64:1892–1899.
- 740 96. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. 2001. Pulmonary inflammation  
741 disrupts surfactant function during *Pneumocystis carinii* pneumonia. *Infect Immun* 69:758–764.
- 742 97. Dumoulin A, Mazars E, Seguy N, Gargallo-Viola D, Vargas S, Cailliez JC, Aliouat EM,  
743 Wakefield AE, Dei-Cas E. 2000. Transmission of *Pneumocystis carinii* disease from  
744 immunocompetent contacts of infected hosts to susceptible hosts. *Eur J Clin Microbiol Infect*  
745 *Dis* 19:671–678.
- 746 98. Chabé M, Dei-Cas E, Creusy C, Fleurisse L, Respaldiza N, Camus D, Durand-Joly I. 2004.  
747 Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR  
748 data demonstrate active replication. *Eur J Clin Microbiol Infect Dis* 23:89–97.
- 749 99. Gigliotti F, Harmsen AG, Wright TW. 2003. Characterization of transmission of *Pneumocystis*  
750 *carinii* f. sp. *muris* through immunocompetent BALB/c mice. *Infect Immun* 71:3852–3856.
- 751 100. Southam DS, Dolovich M, O’Byrne PM, Inman MD. 2002. Distribution of intranasal  
752 instillations in mice: effects of volume, time, body position, and anesthesia. *Am J Physiol Lung*  
753 *Cell Mol Physiol* 282:L833-839.

- 754 101. D'Souza NB, Mandujano JF, Nelson S, Summer WR, Shellito JE. 1995. Alcohol ingestion  
755 impairs host defenses predisposing otherwise healthy mice to *Pneumocystis carinii* infection.  
756 *Alcohol Clin Exp Res* 19:1219–1225.
- 757 102. Harmsen AG, Chen W, Gigliotti F. 1995. Active immunity to *Pneumocystis carinii* reinfection  
758 in T-cell-depleted mice. *Infect Immun* 63:2391–2395.
- 759 103. Cushion MT, Orr S, Keely SP, Stringer JR. 2001. Time between inoculations and karyotype  
760 forms of *Pneumocystis carinii* f. sp. *Carinii* influence outcome of experimental coinfections in  
761 rats. *Infect Immun* 69:97–107.
- 762 104. Vuk-Pavlovic Z, Mo EK, Icenhour CR, Standing JE, Fisher JH, Limper AH. 2006. Surfactant  
763 protein D enhances *Pneumocystis* infection in immune-suppressed mice. *Am J Physiol Lung*  
764 *Cell Mol Physiol* 290:L442-449.
- 765 105. Walzer PD, Kim CK, Foy JM, Linke MJ, Cushion MT. 1988. Inhibitors of folic acid synthesis  
766 in the treatment of experimental *Pneumocystis carinii* pneumonia. *Antimicrob Agents*  
767 *Chemother* 32:96–103.
- 768 106. Sukura A, Soveri T, Lindberg LA. 1991. Superiority of methylprednisolone over  
769 dexamethasone for induction of *Pneumocystis carinii* infection in rats. *J Clin Microbiol*  
770 29:2331–2332.
- 771 107. Shi X, Zhang P, Sempowski GD, Shellito JE. 2011. Thymopoietic and bone marrow response  
772 to murine *Pneumocystis* pneumonia. *Infect Immun* 79:2031–2042.
- 773 108. Walzer PD, Schnelle V, Armstrong D, Rosen PP. 1977. Nude mouse: a new experimental  
774 model for *Pneumocystis carinii* infection. *Science* 197:177–179.
- 775 109. Durand-Joly I, Aliouat EM, Recourt C, Guyot K, François N, Wauquier M, Camus D, Dei-Cas  
776 E. 2002. *Pneumocystis carinii* f. sp. *hominis* is not infectious for SCID mice. *J Clin Microbiol*  
777 40:1862–1865.

778 110. Furuta T, Ueda K, Fujiwara K, Yamanouchi K. 1985. Cellular and humoral immune responses  
779 of mice subclinically infected with *Pneumocystis carinii*. *Infect Immun* 47:544–548.

780 111. Evans HM, Garvy BA. 2018. The trophic life cycle stage of *Pneumocystis* species induces  
781 protective adaptive responses without inflammation-mediated progression to pneumonia. *Med*  
782 *Mycol* 56:994–1005.

783 112. Cushion MT, Ashbaugh A, Hendrix K, Linke MJ, Tisdale N, Sayson SG, Porollo A. 2018.  
784 Gene Expression of *Pneumocystis murina* after Treatment with Anidulafungin Results in  
785 Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating  
786 a Requirement for Ascus Formation for Proliferation. *Antimicrob Agents Chemother*  
787 62:e02513-17.

788 113. Evans HM, Bryant GL, Garvy BA. 2016. The life cycle stages of *Pneumocystis murina* have  
789 opposing effects on the immune response to this opportunistic, fungal pathogen. *Infect Immun*  
790 84:3195–3205.

791 114. Cushion MT. 2010. Are members of the fungal genus *pneumocystis* (a) commensals; (b)  
792 opportunists; (c) pathogens; or (d) all of the above? *PLoS Pathog* 6:e1001009.

793 115. Linke MJ, Ashbaugh A, Collins MS, Lynch K, Cushion MT. 2013. Characterization of a  
794 distinct host response profile to *Pneumocystis murina* asci during clearance of *pneumocystis*  
795 pneumonia. *Infect Immun* 81:984–995.

796 116. Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N. 2015. Type I IFNs  
797 Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during  
798 *Pneumocystis* Lung Infection in Mice. *J Immunol* 195:5347–5357.

799 117. 2017. Évaluation des actes de diagnostic biologique de la pneumocystose (*Pneumocystis*  
800 *jirovecii*). Haute Autorité de Santé.

801 118. Cissé OH, Ma L, Wei Huang D, Khil PP, Dekker JP, Kutty G, Bishop L, Liu Y, Deng X,  
802 Hauser PM, Pagni M, Hirsch V, Lempicki RA, Stajich JE, Cuomo CA, Kovacs JA. 2018.  
803 Comparative Population Genomics Analysis of the Mammalian Fungal Pathogen  
804 *Pneumocystis*. *mBio* 9.

805 119. Ma L, Chen Z, Huang DW, Kutty G, Ishihara M, Wang H, Abouelleil A, Bishop L, Davey E,  
806 Deng R, Deng X, Fan L, Fantoni G, Fitzgerald M, Gogineni E, Goldberg JM, Handley G, Hu  
807 X, Huber C, Jiao X, Jones K, Levin JZ, Liu Y, Macdonald P, Melnikov A, Raley C, Sassi M,  
808 Sherman BT, Song X, Sykes S, Tran B, Walsh L, Xia Y, Yang J, Young S, Zeng Q, Zheng X,  
809 Stephens R, Nusbaum C, Birren BW, Azadi P, Lempicki RA, Cuomo CA, Kovacs JA. 2016.  
810 Genome analysis of three *Pneumocystis* species reveals adaptation mechanisms to life  
811 exclusively in mammalian hosts. *Nat Commun* 7:10740.

812 120. Russell WMS, Burch RL, Universities Federation for Animal Welfare. 1992. The Principles of  
813 humane experimental technique. Universities Federation for Animal Welfare,  
814 Wheathampstead.

815